EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation

Young Joo Lee iD, Woojin Kim iD, Soomin Hong iD, Yong Jae Lee iD, Jung-Yun Lee iD, Sang Wun Kim iD, Sunghoon Kim iD, Young Tae Kim iD, Eun Ji Nam iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e80 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Young Joo Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Women's Cancer Center, Yonsei Cancer Center, Institute of Women's Life Medical Science, Yonsei University Co…. Hauptthemen laut MEDLINE: CA-125 Antigen, WAP Four-Disulfide Core Domain Protein 2, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NRF, YUCM, Roche Diagnostics Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate the efficacy of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in predicting survival outcomes based on breast cancer gene (BRCA) mutational status in epithelial ovarian cancer. METHODS: Medical records of 448 patients diagnosed with epithelial ovarian cancer at a single tertiary institution in Korea were retrospectively analyzed. Area under the curve, sensitivity, specificity, and accuracy were assessed using the CA125 and HE4 values after surgery and 3 cycles of chemotherapy to predict 1-year survival based on the BRCA mutational status. Kaplan-Meier analysis was used to obtain progression-free and overall survival to evaluate CA125 and HE4 effectiveness in predicting survival outcomes. RESULTS: A total of 423 patients were analyzed, including 180 (42.6%) who underwent interval debulking surgery (IDS) and 243 (57.4%) who underwent primary debulking surgery (PDS). BRCA mutations were observed in 37 (15.2%) and 44 (22.4%) patients in the PDS and IDS groups, respectively. CA125 and HE4 normalization demonstrated the highest specificity in patients with or without BRCA mutations, with specificities of 97.1% and 99.1% in the PDS group and 78.6% and 86.2% in the IDS group, respectively. Normalizing HE4 alone may be an effective prognostic marker, with an area under the curve of 0.774 and specificity of 75.0%, in patients with BRCA mutations. CONCLUSION: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-125 AntigenWAP Four-Disulfide Core Domain Protein 2Carcinoma, Ovarian EpithelialOvarian NeoplasmsBiomarkers, TumorMutationCytoreduction Surgical ProceduresHumansFemaleMiddle AgedRetrospective StudiesPrognosisAdultAgedMembrane ProteinsProteinsGenes, BRCA1BRCA1 Protein

Stichwörter der Autor:innen

BRCA1 ProteinBRCA2 ProteinBiomarkers, TumorCA-125 AntigenCarcinoma, Ovarian Epithelial

Substanzen

CA-125 AntigenWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanBiomarkers, TumorMUC16 protein, humanMembrane ProteinsProteinsBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Women's Cancer Center, Yonsei Cancer Center, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Korea Medical Institute, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Women's Cancer Center, Yonsei Cancer Center, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. nahmej6@yuhs.ac.

ORCID-Profile: Young Joo Lee, Woojin Kim, Soomin Hong, Yong Jae Lee, Jung-Yun Lee, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Eun Ji Nam

Förderung

  • NRF
  • YUCM
  • Roche Diagnostics Korea
  • National Research Foundation of Korea
  • Yonsei University College of Medicine

Zitieren

APA

Lee, Y. J., Kim, W., Hong, S., Lee, Y. J., Lee, J. Y., Kim, S. W., Kim, S., Kim, Y. T., & Nam, E. J. (2024). The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e80

Vancouver

Lee YJ, Kim W, Hong S, Lee YJ, Lee JY, Kim SW, et al. The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e80

BibTeX
@article{Lee2024,
  author = {Lee, Young Joo and Kim, Woojin and Hong, Soomin and Lee, Yong Jae and Lee, Jung-Yun and Kim, Sang Wun and Kim, Sunghoon and Kim, Young Tae and Nam, Eun Ji},
  title = {The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e80}
}
Kostenlos starten →